Your browser doesn't support javascript.
Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach.
Kimura, Yayoi; Nakai, Yusuke; Shin, Jihye; Hara, Miyui; Takeda, Yuriko; Kubo, Sousuke; Jeremiah, Sundararaj Stanleyraj; Ino, Yoko; Akiyama, Tomoko; Moriyama, Kayano; Sakai, Kazuya; Saji, Ryo; Nishii, Mototsugu; Kitamura, Hideya; Murohashi, Kota; Yamamoto, Kouji; Kaneko, Takeshi; Takeuchi, Ichiro; Hagiwara, Eri; Ogura, Takashi; Hasegawa, Hideki; Tamura, Tomohiko; Yamanaka, Takeharu; Ryo, Akihide.
  • Kimura Y; Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
  • Nakai Y; Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
  • Shin J; Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
  • Hara M; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Takeda Y; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Kubo S; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Jeremiah SS; Department of Pulmonology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Ino Y; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Akiyama T; Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
  • Moriyama K; Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
  • Sakai K; Advanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
  • Saji R; School of Medicine Medical Course Emergency Medicine, Yokohama City University, Yokohama, 236-0004, Japan.
  • Nishii M; School of Medicine Medical Course Emergency Medicine, Yokohama City University, Yokohama, 236-0004, Japan.
  • Kitamura H; School of Medicine Medical Course Emergency Medicine, Yokohama City University, Yokohama, 236-0004, Japan.
  • Murohashi K; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, 236-0051, Japan.
  • Yamamoto K; Department of Pulmonology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Kaneko T; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, 236-0051, Japan.
  • Takeuchi I; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Hagiwara E; Department of Pulmonology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
  • Ogura T; School of Medicine Medical Course Emergency Medicine, Yokohama City University, Yokohama, 236-0004, Japan.
  • Hasegawa H; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, 236-0051, Japan.
  • Tamura T; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, 236-0051, Japan.
  • Yamanaka T; Influenza Research Center, National Institute of Infectious Diseases, Musashimurayama, Tokyo, 208-0011, Japan.
  • Ryo A; Department of Immunology, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan.
Sci Rep ; 11(1): 20638, 2021 10 19.
Article in English | MEDLINE | ID: covidwho-1475483
ABSTRACT
The COVID-19 pandemic is an unprecedented threat to humanity that has provoked global health concerns. Since the etiopathogenesis of this illness is not fully characterized, the prognostic factors enabling treatment decisions have not been well documented. Accurately predicting the progression of the disease would aid in appropriate patient categorization and thus help determine the best treatment option. Here, we have introduced a proteomic approach utilizing data-independent acquisition mass spectrometry (DIA-MS) to identify the serum proteins that are closely associated with COVID-19 prognosis. Twenty-seven proteins were differentially expressed between severely ill COVID-19 patients with an adverse or favorable prognosis. Ingenuity Pathway Analysis revealed that 15 of the 27 proteins might be regulated by cytokine signaling relevant to interleukin (IL)-1ß, IL-6, and tumor necrosis factor (TNF), and their differential expression was implicated in the systemic inflammatory response and in cardiovascular disorders. We further evaluated practical predictors of the clinical prognosis of severe COVID-19 patients. Subsequent ELISA assays revealed that CHI3L1 and IGFALS may serve as highly sensitive prognostic markers. Our findings can help formulate a diagnostic approach for accurately identifying COVID-19 patients with severe disease and for providing appropriate treatment based on their predicted prognosis.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Biomarkers / Gene Expression Profiling / Proteomics / COVID-19 Serological Testing / COVID-19 Subject: Biomarkers / Gene Expression Profiling / Proteomics / COVID-19 Serological Testing / COVID-19 Type of study: Diagnostic study / Prognostic study Language: English Journal: Sci Rep Clinical aspect: Prediction / Prognosis Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Biomarkers / Gene Expression Profiling / Proteomics / COVID-19 Serological Testing / COVID-19 Subject: Biomarkers / Gene Expression Profiling / Proteomics / COVID-19 Serological Testing / COVID-19 Type of study: Diagnostic study / Prognostic study Language: English Journal: Sci Rep Clinical aspect: Prediction / Prognosis Year: 2021
...